| 000 | 01638 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515150202.0 | ||
| 264 | 0 | _c20091117 | |
| 008 | 200911s 0 0 eng d | ||
| 022 | _a1468-2060 | ||
| 024 | 7 |
_a10.1136/ard.2008.092833 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRadstake, T R D J | |
| 245 | 0 | 0 |
_aFormation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _cNov 2009 |
||
| 300 |
_a1739-45 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Anti-Idiotypic _xbiosynthesis |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xblood |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRadioimmunoassay _xmethods |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aSvenson, M | |
| 700 | 1 | _aEijsbouts, A M | |
| 700 | 1 | _avan den Hoogen, F H J | |
| 700 | 1 | _aEnevold, C | |
| 700 | 1 | _avan Riel, P L C M | |
| 700 | 1 | _aBendtzen, K | |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 68 _gno. 11 _gp. 1739-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/ard.2008.092833 _zAvailable from publisher's website |
| 999 |
_c18476503 _d18476503 |
||